2-FDCK Stats & Data

The synthesis of 2-fluorodeschloroketamine was first described in a 2013 scientific paper as part of a broader effort to synthesize and evaluate novel anesthetic compounds based on ketamine and its structural analogues. Despite this early documentation, the compound's origins as a recreational substance remain poorly established. It first emerged on the online research chemical market around 2017, where it was marketed as a legal alternative to ketamine. Its introduction followed the successful market entry of the related analogue deschloroketamine. The compound was first formally notified to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2016, alongside 65 other new psychoactive substances. Due to its relatively recent emergence, limited scientific research has been conducted on the compound. In January 2023, the Israeli biotechnology company Clearmind Medicine Inc. announced the completion of a preclinical study examining 2-fluorodeschloroketamine in a rat model of depression, with results suggesting the compound produced longer-lasting antidepressant effects compared to ketamine.

The toxicity and long-term health effects of recreational 2-Fluorodeschloroketamine use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-Fluorodeschloroketamine has very little history of human usage. Anecdotal evidence from people who have tried 2-Fluorodeschloroketamine within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 7 experience reports (7 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 7 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

From 37 of 45 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 17 reports filed under 2-FDCK

Too few reports for bars: these combinations come from 17 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• THC 4 of 17
• Alcohol 3 of 17

Most common forms and preparations, as a share of the 12 reports that give one

Too few reports for bars: these forms come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Powder / Crystals 7 of 12
• Liquid 3 of 12

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 15 reports